Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

TECHNIA AB

Eli Lilly Recruits Leading Swedish Researcher Kaj Blennow to Head Alzheimer’s Project

Eli Lilly recruits Kaj Blennow, leading Alzheimer’s researcher, as VP of neuroscience biomarker development.

Eli Lilly skrotar smärtkandidat – ytterligare omsvängning i pipelinen

Eli Lilly lägger ner utvecklingen av sin P2X7-hämmare i fas II mot smärta. Det är den senaste förändringen i en pipeline som redan genomgått flera större omprio...

Roche joins Medicon Village

Roche and Medicon Village Innovation have signed an agreement for deeper collaboration. “The fact that Roche is now becoming part of this environment further st...

Meribel Pharma Solna

Anocca raises SEK 440 million ahead of clinical cancer trial

Swedish cell therapy biotech Anocca has successfully raised SEK 440 million in a new funding round to support upcoming clinical trials in pancreatic cancer.

New ATMP center inaugurated: “In the future, we will see cell and gene therapies in all clinics”

Karolinska Institutet and Karolinska University Hospital’s new ATMP center was inaugurated in Flemingsberg, south of Stockholm. “The ATMP Center is not just a p...

Introducing ZEISS arivis Pro 4.2

Your solution for advanced image analysis and visualization.

Unmatched performance and flexibility in its class

The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.

From powder to implant

Quality assurance for additively manufactured implants.

ZEISS Microscope has been Optimized for Capturing Subcellular Structures and their Dynamics

Live imaging with uniform super-resolution in all spatial dimensions.

Rekordstor donation till cancerforskning i Lund – ”Once in a lifetime-möjlighet”

Lunds universitet får den största donationen i lärosätets moderna historia, enligt ett pressmeddelande.

Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

Alzinova får FDA:s snabbspår för sitt alzheimervaccin

Biofarmabolaget Alzinovas vaccinkandidat mot Alzheimers sjukdom har beviljar Fast Track-status av USA:s läkemedelsmyndighet FDA.

Webinar: Support Trial Patients Transitioning to the Commercial Space

Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.

The business coach: “We need to learn from our mistakes”

The past year has been challenging for many biotech companies, with several comapanies facing financial stress and bankruptcy. To understand how entrepreneurs c...

Ingrid Lönnstedt: ”The confidence interval and its width”

Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.

Billion-Dollar Deal Sends BioArctic Soaring

Swedish Alzheimer-focused company BioArctic has entered into a licensing collaboration with Novartis regarding a technology aimed at enhancing efficient drug de...

A tiny animal with great importance

From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious care...

Astra Zeneca nådde fas III-mål med ny blodtrycksbehandling

Astra Zeneca rapporterar nya positiva data för baxdrostat mot svårbehandlat högt blodtryck.

Samuel Lagercrantz: ”Geoffrey Hintons farhågor”

”Ska vi få en så ljus framtid som möjligt där AI används på bästa sätt behövs både de som ser risker med den nya tekniken och de som ser sig som teknikoptimiste...

Abbvies storsäljare inom reumatism visade fina resultat mot håravfall

Ett välkänt läkemedel mot reumatism visar tecken på att även vara en effektiv behandling mot fläckvis håravfall.

Astra Zeneca faces potential multimillion-dollar fines in China

Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following ea...